Akero Therapeutics Inc (AKRO)
19.94
-0.80
(-3.84%)
USD |
NASDAQ |
May 17, 16:00
19.94
0.00 (0.00%)
After-Hours: 20:00
Akero Therapeutics Research and Development Expense (Annual): 141.80M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 141.80M |
| December 31, 2022 | 85.28M |
| December 31, 2021 | 81.76M |
| Date | Value |
|---|---|
| December 31, 2020 | 64.92M |
| December 31, 2019 | 37.05M |
| December 31, 2018 | 11.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
37.05M
Minimum
2019
141.80M
Maximum
2023
82.16M
Average
81.76M
Median
2021
Research and Development Expense (Annual) Benchmarks
| 89bio Inc | 122.23M |
| Madrigal Pharmaceuticals Inc | 272.35M |
| Viking Therapeutics Inc | 63.81M |
| Ionis Pharmaceuticals Inc | 899.62M |
| Galectin Therapeutics Inc | 32.13M |